Advertisement
Screener

Veradermics, Inc (MANE) Graph

MANE Revenue Flow

A current filed revenue breakdown could not be established from the retained filing evidence.

  • 2026-06-30: Research and development $18.61M; Operating expenses $29.55M; Income tax $0.00; Net income -$23.50M.
  • 2026-03-31: Research and development $20.93M; Operating expenses $29.86M; Income tax $0.00; Net income -$27.23M.
  • 2025-06-30: Research and development $14.33M; Operating expenses $16.07M; Income tax $0.00; Net income -$15.64M.
  • 2025-03-31: Research and development $11.45M; Operating expenses $12.91M; Income tax $0.00; Net income -$12.40M.

Finer product or service dollar figures and nonoverlapping groupings are shown only where supported by the retained filing evidence. Growth percentages are never converted to revenue dollars.

Historical revenue and expense breakdown

Revenue and expense 3 month

Period endResearch and developmentOperating expensesIncome taxNet income
2026-06-30$18.61M$29.55M$0.00-$23.50M
2026-03-31$20.93M$29.86M$0.00-$27.23M
2025-06-30$14.33M$16.07M$0.00-$15.64M
2025-03-31$11.45M$12.91M$0.00-$12.40M

Revenue and expense 6 month

Period endResearch and developmentOperating expensesIncome taxNet income
2026-06-30$39.53M$59.41M$0.00-$50.73M
2025-06-30$25.78M$28.99M$0.00-$28.05M

Revenue and expense 12 month

Period endResearch and developmentOperating expensesIncome taxNet income
2025-12-31$62.06M$72.35M$0.00-$70.00M
2024-12-31$23.28M$26.78M$0.00-$26.49M

Similar stocks

Stock NameCountryMarket CapPE Ratio
Erasca, Inc. (ERAS)United States$5.073B-19.96
Dianthus Therapeutics, Inc. /DE/ (DNTH)United States$5.082B-27.79
PTC THERAPEUTICS, INC. (PTCT)United States$5.199B-177.07
Edgewise Therapeutics, Inc. (EWTX)United States$4.470B-22.23
Gossamer Bio, Inc. (GOSS)United States$5.355B-0.65
Viking Therapeutics, Inc. (VKTX)United States$4.287B-8.51
Indivior Pharmaceuticals, Inc. (INDV)$4.250B14.09
Cogent Biosciences, Inc. (COGT)United States$5.450B-17.61
Tango Therapeutics, Inc. (TNGX)United States$4.154B-42.53
Oruka Therapeutics, Inc. (ORKA)United States$5.663B-43.76